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Hereditary spherocytosis (HS) originates from defective anchoring ofthe cytoskeletal network to the transmembrane protein complexes ofthe red blood cell (RBC). Red cells in HS are characterized by mem-
brane instability and reduced deformability and there is marked heterogene-
ity in disease severity among patients. To unravel this variability in disease
severity, we analyzed blood samples from 21 HS patients with defects in
ankyrin, band 3, α-spectrin or b-spectrin using red cell indices, eosin-5-
maleimide binding, microscopy, the osmotic fragility test, Percoll density gra-
dients, vesiculation and ektacytometry to assess cell membrane stability, cel-
lular density and deformability. Reticulocyte counts, CD71 abundance, band
4.1 a:b ratio, and glycated hemoglobin were used as markers of RBC
turnover. We observed that patients with moderate/severe spherocytosis
have short-living erythrocytes of low density and abnormally high intercellu-
lar heterogeneity. These cells show a prominent decrease in membrane sta-
bility and deformability and, as a consequence, are quickly removed from the
circulation by the spleen. In contrast, in mild spherocytosis less pronounced
reduction in deformability results in prolonged RBC lifespan and, hence, cells
are subject to progressive loss of membrane. RBC from patients with mild
spherocytosis thus become denser before they are taken up by the spleen.
Based on our findings, we conclude that RBC membrane loss, cellular hetero-
geneity and density are strong markers of clinical severity in spherocytosis.
Introduction
Hereditary spherocytosis (HS) is the most common form of chronic hereditary
hemolytic anemia in the Caucasian population, with an estimated prevalence of
1:2000 – 1:5000.1–3 HS usually originates from mutations in ANK1 (ankyrin),
SLC4A1 (band 3), SPTA1 (α-spectrin), SPTB (b-spectrin) or EPB42 (protein 4.2).1
Anemia in HS may require transfusion(s) and in severe cases splenectomy. A char-
acteristic feature of HS is red blood cell (RBC) membrane instability, which leads to
membrane loss and formation of dense cells with reduced RBC deformability.4–6
Increased RBC density is an important feature of HS7 and is reflected, for example,
by increased mean corpuscular hemoglobin concentration (MCHC).8,9
HS is a very heterogeneous RBC disorder, resulting from a wide range of molecu-
lar defects and characterized by a high degree of heterogeneity in RBC properties
and disease severity.8–12 In fact, considerable differences in disease severity are
reported even between HS patients with identical mutations. It therefore seems rea-
Density, heterogeneity and deformability of
red cells as markers of clinical severity in
hereditary spherocytosis
Rick Huisjes,1 Asya Makhro,2 Esther Llaudet-Planas,3 Laura Hertz,4 Polina
Petkova-Kirova,4 Liesbeth P. Verhagen,1 Silvia Pignatelli,1 Minke A.E. Rab,1
Raymond M. Schiffelers,1 Elena Seiler,2 Wouter W. van Solinge,1 Joan-LLuis
Vives Corrons,3 Lars Kaestner,4,5 Maria Mañú-Pereira,6 Anna Bogdanova2 and
Richard van Wijk1
1Department of Clinical Chemistry and Hematology, University Medical Center Utrecht,
Utrecht University, Utrecht, the Netherlands; 2Red Blood Cell Research Group, Institute of 
Veterinary Physiology, Vetsuisse Faculty and the Zurich Center for Integrative Human
Physiology (ZIHP), University of Zurich, Zurich, Switzerland; 3Red Blood Cell Defects and
Hematopoietic Disorders Unit, Josep Carreras Leukemia Research Institute, Badalona,
Barcelona, Spain; 4Theoretical Medicine and Biosciences, Medical Faculty, Saarland
University, Homburg/Saar, Germany; 5Experimental Physics, Saarland University,
Saarbruecken, Germany and 6Rare Anemia Research Unit. Vall d’Hebron Research
Institution, University Hospital Vall d’Hebron, Barcelona, Spain
ABSTRACT
sonable to assume that the heterogeneity in disease sever-
ity is not only a reflection of particular genotypes but is
also affected by other factors that control RBC properties.
Healthy RBC become increasingly dense during their
lifespan,13,14 but this process is accelerated in HS.1 Shedding
of essentially hemoglobin-free vesicles results in an
increase in MCHC and a corresponding increase in RBC
density and intracellular viscosity.13,15 Electrogenic potassi-
um leakage also contributes to RBC dehydration in HS
patients and is not compensated by an accumulation of
Na+.16,17 As a result, the intracellular K+ concentration in the
RBC of HS patients is approximately 13 mmol/L lower
than that in the cells of healthy subjects,16 which results in
net ion and water loss. Compensatory activation of Na,K-
ATPase in the RBC of patients is insufficient to prevent the
loss of K+ and dissipation of K+/Na+ gradients. The func-
tion of other electroneutral ion transporters (KCC, NKCC,
Na/Li exchanger) in RBC of HS patients was reported to
be indistinguishable from that of cells of healthy con-
trols.16,18
In this study, we investigated a unique and genetically
well-diagnosed group of HS patients in whom we per-
formed an in-depth analysis of RBC properties, such as
membrane instability, cellular density, cellular heterogene-
ity, vesiculation, turnover and lifespan. The data obtained
were then correlated to clinical manifestations of HS in
both non-splenectomized and splenectomized patients, in
order to identify markers of disease severity. Our results
indicate that clinical severity in HS cannot be solely attrib-
uted to the protein harboring the mutation, but rather to
the stability of the whole cytoskeletal network. RBC den-
sity, heterogeneity and deformability were identified as
potential markers of severity. We found that the presence
of dense RBC is strongly associated with milder manifes-
tations of HS. We hypothesize that unstable RBC from
patients with clinically more severe disease are removed




Patients previously diagnosed with HS were enrolled in the
CoMMiTMenT-study (http://www.rare-anaemia.eu/). This study
was approved by the Medical Ethical Research Board of the
University Medical Center Utrecht, the Netherlands, under refer-
ence code 15/426M and by the Ethical Committee of Clinical
Investigations of Hospital Clinic, Spain, (IDIBAPS) under reference
code 2013/8436. 
Hemocytometry analysis
Hemocytometry parameters were analyzed on an Abbott
Sapphire cell analyzer (Abbott Diagnostics Division, Santa Clara,
CA, USA) and ADVIA 2120 (Hematology System, Siemens
Healthcare Diagnostics, Forchheim, Germany).
Capillary-based measurements of mean corpuscular
volume and mean corpuscular hemoglobin 
concentration
Triplicate heparinized blood samples were put in capillaries and
centrifuged for 5 min at 12,000 rpm (Hematocrit 20, Hettich
Zentrifugen). Mean corpuscular volume (MCV) was calculated
using the formula MCV = hematocrit/RBC number. MCHC was
calculated using the formula MCHC = hemoglobin/hematocrit. 
Separation on a Percoll density gradient and 
determination of intracellular potassium levels
Intact blood samples were layered over a 90% isotonic Percoll
solution containing plasma-like components as described else-
where.19 Briefly, Percoll density gradient and RBC separation were
performed during centrifugation at 50,000 g for 15 min. (Sorvall
RC 5C plus, rotor SM-24). Intracellular potassium was measured
using an Instrumentation Laboratory IL943 Flame Photometer, as
described by Jokinen et al.20
Osmotic gradient ektacytometry, the osmotic fragility
test and eosin-5-maleimide binding
Osmotic gradient ektacytometry measurements of RBC from
healthy controls and HS patients were obtained using the
Osmoscan module on a Lorrca MaxSis (Mechatronics, The
Zwaag, the Netherlands) as described elsewhere.5,21 The osmotic
fragility test was carried out as previously described by Parpart et
al.22 and eosin-5-maleimide (EMA) binding was determined
according to previously published protocols.12,23
Red blood cell production, heterogeneity, vesiculation
and turnover rate markers 
RBC were stained with anti-CD71 and isotype controls and
were subsequently measured using a BD FACS Gallios.24
Measuring glycated hemoglobin (HbA1c) is an established way to
acquire information about RBC clearance and RBC age in research
on hemolytic anemias.15,25 HbA1c levels were measured using a
Menarini/ARKRAY HA-8180V. The band 4.1a:b ratio was detect-
ed in RBC membrane lysates after protein separation by inverse
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) (15-7.5%) and visualization of protein bands using
Coomassie blue staining. RBC projected area and its heterogeneity
were evaluated by microscopy as described elsewhere.26,27 RBC
vesicles were identified in plasma preserved with citrate-phos-
phate-dextrose-adenine19 by staining them with mouse anti-
human CD235a-APC and measured using a Beckman Coulter
CytoFLEX flow cytometer (Online Supplementary Figure S1).
Statistical analysis and phenotype correlations
One-way analysis of variance with post-hoc correction (Tukey
test) was used to compare sample means and the Fisher exact test
was applied to determine whether clinical severity was propor-
tionally distributed along the different genotypes. In non-splenec-
tomized patients, clinical severity was assessed based on: (i)
hemoglobin concentration and (ii) reticulocyte count, as previous-
ly defined by Bolton-Maggs et al.11 (i.e., mild and
moderate/severe). To prevent any confounding by splenec-
tomized patients, phenotype correlations were only carried out
for unsplenectomized HS patients. 
Results
Baseline characteristics and red cell features 
of patients with hereditary spherocytosis
Twenty-one patients with HS were included in this
study and categorized according to clinical severity (Table
1).11 HS was confirmed by targeted next-generation
sequencing of the seven genes most commonly mutated
in HS28. Splenectomy or a moderate/severe expression of
disease was statistically overrepresented in patients with
mutations in ANK1 and SPTB (P<0.05). Therefore, the
phenotypic expression of HS due to ANK1 and SPTB
mutations appears to be more severe than that of HS due
to SLC4A1 and/or SPTA1 defects. Decreased EMA stain-
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ing, reflecting band 3 protein loss, was seen in all patients.
Patients with SPTA1 mutations tended to have greater
EMA staining (Figure 1A), although the number of
patients was too low to draw firm conclusions. The max-
imal deformability of RBC, reflected by a decrease in
maximal elongation index (EImax) as determined by the
Osmoscan, was decreased in all HS patients compared to
that in healthy controls. This decrease was more pro-
nounced in patients with ANK1 and SPTBmutations than
in patients with mutations in SPTA or SCL4A1 (Figure
1B). On the other hand, cells from patients with SLC4A1
mutations tended to be more dehydrated as their Ohyper
values (hypertonic osmolarity at 50% of EImax) were lower
than those in both control blood samples and patients
with SPTA1 mutations (Figure 1C). The latter patients
also showed the least pronounced loss of surface area-to-
volume ratio, reflected by a normal Omin (hypotonic
osmolarity where EI is minimal) (Figure 1D) on the
Osmoscan and normal results in the osmotic fragility test
(50% lysis point) (Figure 1E).  Membrane stability was
compromised in all other HS patients.
As expected, RBC turnover was increased in all
patients: reticulocyte counts were high (Table 1) and the
band 4.1a:b ratio, a marker of aging, was lower in all
patients than in healthy controls (Table 1). 
The heterogeneity of the RBC, reflected by the red
blood cell distribution width (RDW), was greater in
patients with HS than in healthy controls (Figure 1F) as
was the MCHC (Figure 1G). Intracellular K+ content was
reduced in all patients but tended to be higher in HS
patients with SPTA1 mutations (Figure 1H).
An increase in heterogeneity in cell projected areas
(mean projected area distribution width, MPA DW)
(Figure 2A) and a decrease in absolute mean values in pro-
jected area (MPA) (Figure 2B) were seen in all HS patients
compared to those in controls. Patients with SLC4A1 and
SPTA1 mutations had cellular projected areas more simi-
lar to those of the healthy control group (Figure 2A, B).
Table 1. Hemocytometry, chemistry parameters, cell-age markers and genotypes of patients with mild or moderate/severe hereditary spherocytosis (HS) and
splenectomized HS patients included in this study. 
N.  Sex    Age    Genotype                                                       Hb        RBC   Hct     MCV    Ret   MCHC    RDW     EMA     Omin      EImax        Ohyper      OFT        Band     CD71
              (years)                                                                    (g/dL)     (1012   (%)      (fL)     (%)    (g/L)    (%CV)     (%)    (mOsmo  (A.U.)   (mOsmo  (g/L    4.1/4.2    (%)
                                                                                                             /L)                                                                          l/L)                     l/L)     NaCl)       ratio 
                                                                                                                                                                                                                                                (A.U.)
Mild HS11
1      ♂        75       ANK1 c.344T>C p.Leu115Pro                              136           4.1      n.a.        n.a.       7.2       n.a.         16.2          85          162        0.555         457         7.0            0.70          0.8
2      ♂        46       SLC4A1 c.1030C>T p.Arg344*                              153           4.7      n.a.        n.a.       3.2       n.a.         15.2          71          163        0.563         417         6.6            0.87          1.4
3      ♂        40       SLC4A1 c.1421C>A p.Ala474Asp                 140           4.9      n.a.        n.a.       4.0       n.a.         12.3          93          162        0.557         427         5.7            0.99          1.2
4      ♀        55       SLC4A1 c.2057+1G>A (splicing)                 136           4.0     36.5       91.1      7.8       372         14.0          73          158        0.554         405         6.4            0.82          2.7
5      ♀        18       SLC4A1 c.2057+1G>A (splicing)                 131           3.7     35.7       96.9      9.4       367         13.1          77          166        0.569         410         6.1            0.84          1.4
6      ♂        58       SLC4A1 c.2348T>A p.Ile783Asn                            132           4.1     36.5       88.4      8.9       363         15.7          68          169        0.548         429         6.8            n.a.          3.5
7      ♂        40       SPTA1 c.678G>A p.Glu227fs + αLELY                    127           4.1     35.9       87.8      5.8       355         15.0          94          175        0.600         453         5.6            0.84          0.9
8      ♂        54       SPTA1 c.[4339-99C>T; c.4347G>T]                121           3.5     34.7       98.3      3.9       348         15.3          94          160        0.566         458         5.7            n.a.          0.9
                               p.[(?; Lys1449Asn)]; c.4339-99C>T p.(?)
Moderate/severe HS11
9      ♂         4        ANK 1 c.341C>T p.Pro114Leu                      116           3.8     30.0       80.1      9.1       386         14.5          72          162        0.509         398         6.6            0.72          2.2
10    ♀         3        ANK1 c.1943delC p.Ala648fs                        117          4.02    36.3       90.4     11.9      321         21.1          59          164        0.503         424         6.6            n.a.          0.2
11    ♂         5        ANK1 c.2394_2397delCAGT p.Ser799fs              120           4.1     32.2       78.6     18.4      372         25.4          67          185        0.472         462         7.8            n.a.          7.3
12    ♀        26       ANK1 c.2559-2A>G (splicing)                    102           3.3     29.4       89,5     18.3      346         24.1          84          170        0.537         446         6.4            0.60          5.3
13    ♂         1        SPTB c.154delC p.Arg52fs                              86           3.38    30.2       89.5     11.9      284         24.7          66          168        0.532         456         5.7            n.a.          4.8
14    ♂         3        SPTB c.2470C>T p.Gln824*                           78            2.9     23.7       81.9     10.6      328         23.8          71          180        0.534         475         6.7            n.a.          2.9
15    ♂         4        SPTB c.5937+1G>A p.(?)                               84           3.09    27.7       89.7     16.7      303         23.4          74          173        0.541         459         7.0            n.a.          5.5
16    ♀        42       SPTA1 c.2755G>T p.Glu919* + αLELY        113           3.5     31.7       91.8      8.2       355         16.0          89          178        0.567         471         5.9            n.a.          2.1
Splenectomized HS11
17    ♂        31       ANK1 c.341C>T p.Pro114Leu                       152           4.9     84.7       41.9      8.4       362         11.8          76          179        0.533         437         7.4            1.08          0.1
18    ♀        46       ANK1 c.344T>C p.Leu115Pro                               143           4.6      n.a.        n.a.       2.8       n.a.         12.4          74          158        0.590         423         7.4            1.18          0.2
19    ♀        84       SLC4A1 c.2057+1G>A (splicing)                 160           4.8    121.8      45.1     12.6      354         11.0          67          164        0.565         417         7.1            1.07          0.2
20    ♂        71       SPTB c.2136_2137delinsTT                          164          4.84   100.9      48.8      2.2       337         13.2          77          173        0.509         445         7.3            0.99          0.3
21    ♂        40       SPTB c.3449G>A p.Trp1150*                        163          4.94    92.0       45.5     12.2      359         11.9          73          183        0.512         440         7.8            1.22          0.3
Clinical severity in non-splenectomized HS patients was assigned according to Bolton-Maggs et al.11 on the basis of (i) hemoglobin concentration and (ii) reticulocyte count. Mild HS was defined
as hemoglobin levels between 110–150 g/L, moderate HS as hemoglobin levels between 80–120 g/L and severe HS as hemoglobin levels lower than 80 g/L. HS patients with hemoglobin levels
between 110 and 120 g/L were categorized as having mild or moderate disease on the basis of their reticulocyte levels (i.e., lower or higher than 6% reticulocytes). Novel mutations are displayed
in bold font and the pathogenicity of novel missense variants was predicted with SIFT, PolyPhen-2, and MutationTaster (results not shown). Notation of αLELY represents SPTA1 c.[5572C>G; 6531-
12C>T] p.[(Leu1858Val);(?)].  N: number; Hb: hemoglobin; RBC: red blood cells; Hct: hematocrit; MCV; mean corpuscular volume; Rct: reticulocytes; MCHC: mean corpuscular hemoglobin con-
centration; RDW: red cell distribution width; EMA: eosin-5′-maleimide; %CV: percent coefficient of variation; HS: hereditary spherocytosis; n.a.: not available.
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Patients with HS presented with greater heterogeneity in
cell density compared with healthy subjects, showing
more subfractions of the M fraction and a broader distri-
bution width of the M fraction (Figure 2C-E). These
changes were more pronounced in patients with muta-
tions in ANK1 and SPTA1. Furthermore, the M fraction of
patients with SLC4A1 mutations was lower than that of
healthy controls or other HS patients (Figure 2F, Online
Supplementary Figure S2). 
In summary, specific changes were observed in param-
eters associated with membrane stability, stiffness and
deformability, as well as RBC heterogeneity in our cohort
of HS patients.
Red blood cell markers of severity of hereditary 
spherocytosis 
As described in Table 1, the severity of HS in non-
splenectomized patients was determined based on the
decrease in hemoglobin concentration and increase in
reticulocyte count.11 In our patients hemoglobin concen-
tration correlated positively with MCHC (Figure 3A).
Inverse correlations were observed between hemoglo-
bin and RDW (Figure 3B), and between hemoglobin and
reticulocyte count (Figure 3C). Furthermore, inverse cor-
relations were observed between hemoglobin and
parameters defining RBC hydration status such as intra-
cellular K+ and Ohyper (Figure 3D, E). 
Decreases in RBC lifespan were assessed by a reduc-
tion in changes in HbA1c in non-splectomized patients
with severe HS, whereas in patients with mild disease
manifestations or in splenectomized patients HbA1c
levels were within the normal range (Figure 4A). 
Patients with moderate/severe HS had less deformable
RBC, reflected by lower Elmax values, than patients with
mild HS or splenectomized patients (Figure 4B). The
RBC of patients with mild HS also tended to be more
Phenotypic markers for hereditary spherocytosis
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Figure 1. Basic characteristics (median ± range) of healthy controls and patients with hereditary spherocytosis. Patients with hereditary spherocytosis (HS) were
grouped as a whole and according to their affected genes [ANK1 (ankyrin), SLC4A1 (band 3), SPTB (b-spectrin) and SPTA1 (α-spectrin)]. Blue circles represent
healthy controls, black circles represent unsplenectomized HS patients and red circles represent splenectomized HS patients. The gray range indicates the reference
range for healthy controls. (A) Eosin-5′-maleimide (EMA)-binding (%), (B) maximum deformability (EImax), (C) hydration state of the red blood cells reflected by Ohyper,
(D) osmotic fragility measured by osmotic gradient ektacytometry and reflected by Omin, (E) 50% lysis point in the osmotic fragility test, (F) red blood cell distribution
width (RDW) (percent coefficient of variation, %CV), (G) mean corpuscular hemoglobin concentration (MCHC) by capillary measurements (g/L) (%CV), (H) intracellular





dehydrated, based on the Ohyper measurements (Figure
4C). In line with this, patients with mild HS showed
higher MCHC values than moderately/severely affected
patients (Figure 4D) and had a higher density of the M
fraction, based on this latter’s position within the Percoll
gradient (Figure 4E, Online Supplementary Figure S2). 
Based on reduced MPA, membrane loss was more pro-
nounced in patients with moderate/severe HS (Figure
4F). In line with this, the number of RBC vesicles detect-
ed in the plasma of patients with moderate/severe HS
was higher than that in patients with mild HS (Figure
4G). However, no difference in EMA staining was
observed between patients with mild or
moderate/severe HS (Figure 4C). Intercellular hetero-
geneity (RDW and MPA DW) was increased in patients
with moderate/severe HS compared to those with mild
HS and healthy controls (Figure 4I, J). 
In summary, the RBC of patients with more severe
expression of the disease had a reduced lifespan and less
stable membrane. Their cells were smaller and more
heterogeneous in size and density. Strikingly, patients
with mild HS had denser RBC with higher MCHC
(Figure 4D, E).
Effect of splenectomy on red blood cell markers 
of disease severity 
Performed in patients with moderate/severe HS,
splenectomy results in an increase in hemoglobin levels
and erythrocyte counts (data not shown). In our cohort
splenectomy was also associated with a decrease in RDW
(Figure 5A) and normalization of RBC morphology (Online
Supplementary Figures S3 and S4). The survival of RBC
from splenectomized HS patients, as assessed by HbA1c
content or band 4.1a:b ratio, was found to be increased
(Figure 5B, C).
Several parameters remained unaffected by splenecto-
my. Splenectomy did not alter MCHC (Figure D) or intra-
cellular K+ levels (Figure 5E) and did not correct band 3 loss
(Figure 5F). It also did not affect deformability (no effect
on Elmax or Ohyper) (Figure 5G, H). However, the cells did sur-
vive for a longer time in the circulation despite an increase
in osmotic fragility (Figure 5I). 
Discussion
This comprehensive study in a well-characterized
cohort of patients offers insight into the variable pheno-
typic manifestations of HS, possible causes of clinical het-
erogeneity and severity, and the impact of splenectomy.
We show here that strong markers of moderate/severe
expression of HS are: (i) lower RBC density, reflected by
differences in MCHC and fractionation of RBC on the
Percoll density gradient; (ii) reduced RBC deformability
R. Huisjes et al.
342 haematologica | 2020; 105(2)
A B C
D E F
Figure 2. Red blood cell heterogeneity in hereditary spherocytosis. Red blood cell (RBC) heterogeneity was measured in healthy controls and patients with hereditary
spherocytosis (HS) by microscopy (A, B) and Percoll density gradients (C-F). HS patients were grouped according to their affected genes [ANK1 (ankyrin), SLC4A1
(band 3), SPTB (b-spectrin) and SPTA1 (α-spectrin)]. (A) Mean projected area distribution width (MPA DW). (B) Mean projected area (MPA). (C) An example of a blood
sample from a patient with HS and a healthy control. On the samples the young RBC fraction, the main RBC fraction (M fraction) and dense RBC fractions are des-
ignated with green, blue and red lines, respectively. The M fraction is subdivided into subfractions (M1, M2, etc.). The position of the M fraction is calculated from
the position of the most intense (n arbitrary units, a.u.) subfraction relative to the total length of the Percoll column. The HS patient has seven RBC subfractions, and
the position of the most intense subfraction (i.e. subfraction M3) is lower than in the control subject (i.e. subfraction M1). (D) The number of subfractions in the RBC
density gradient. (E) Fraction distribution width (%). (F) Position of the M fraction (%). Significant differences are noted: *P≤0.05, †P≤0.01 or ‡P≤0.001. 
and increased membrane loss, as determined by RBC vesi-
cle numbers and a decrease in MPA; and (iii) heterogeneity
in the RBC population reflected by differences in RDW
and fractionation of RBC using a Percoll gradient.
We conclude that patients with moderate/severe HS
have short-lived RBC of lower density and abnormally
high intercellular heterogeneity, whereas patients with
mild HS have a less pronounced reduction in RBC
deformability resulting in the cells living longer and being
subject to progressive loss of membrane. RBC from
patients with mild HS thus become denser before they are
taken up by the spleen.
Genotype to phenotype correlations in hereditary 
spherocytosis
While previous studies were limited to protein analysis
by SDS-PAGE,12 we used next-generation sequencing to
establish the cause of HS. This enabled us to define the
primary genetic defect unequivocally, in contrast to other
conventional techniques such as SDS-PAGE, which may
lead to confounding results as it may be influenced by
secondary protein defects in HS. Regardless of the under-
lying mutation, all patients shared common features such
as increases in reticulocyte counts and MCHC, dehydra-
tion and increases of RBC density and heterogeneity and
an overall reduction in deformability of the RBC due to
destabilization of cytoskeletal structures.1,29 We also
observed that red cell size, intracellular K+ content and
reticulocyte counts did not differ between patients with
SLC4A1, ANK1, SPTB and SPTA1 mutations (Figures 1H
and 2B, Table 1). Within one group of patients with the
same mutated protein we noted marked differences in
severity and clinical manifestations of the disease, with
the ANK1 group showing the greatest diversity. We also
noted that patients with SPTA1 mutations had a less
severe phenotype (based on hemoglobin level, reticulo-
cyte count, RDW, intracellular K+, and EMA staining)
compared to the other patients. This is in contrast with
the more severe disease phenotype of patients with
SPTA1 mutations reported in other studies.30 Similarly,
our patients with SPTB mutations presented with nor-
mal MCHC values, whereas in other studies MCHC was
shown to be elevated in patients carrying SPTB muta-
tions.31 Given the relatively small numbers of patients
within each group we cannot draw firm conclusions on
links between genotype and phenotypic expression. 
Red blood cell density as a marker of clinical severity
Decreased hemoglobin, hematocrit and RBC counts
associated with increased markers of hemolysis and ery-
thropoietic activity were previously reported as markers
of HS severity.9 Among the molecular mechanisms defin-
ing severity of HS, a major role was assigned to RBC
membrane instability and loss of membrane proteins28
(MCHC, EMA test, SDS-PAGE), along with decreased
deformability as measured by osmotic gradient ektacy-
tometry.5 In our cohort, increased disease severity was
associated with membrane instability and extensive mem-
brane and band 3 protein loss over a shorter time (Figure
4B, G-I). RBC turnover in patients with severe HS was
reflected by a decrease in HbA1c levels, which were high-
er than those in patients with mild HS (Figure 4A). The
RBC in patients with moderate/severe HS had lower
MCHC than those of patients with mild HS (Figures 3A
and 4D). The average M fraction density of RBC from
patients with moderate/severe HS did not differ from that
of cells of healthy controls, whereas the cells from patients
with mild HS showed an increase in density (Figure 4E)
Phenotypic markers for hereditary spherocytosis
haematologica | 2020; 105(2) 343
Figure 3. Red blood cell parameters and their relationship to clinical severity in unsplenectomized hereditary spherocytosis patients. (A) Mean corpuscular hemo-
globin concentration (MCHC) (g/L), (B) red blood cell distribution width (RDW) (percent  coefficient of variation, %CV), (C) reticulocytes (%), (D) intracellular potassium




and lower deformability as they “aged”, spending more
time in the circulation getting more “senescent” than the
highly unstable cells of patients with severe HS. Thus,
RBC lifespan and decrease in Elmax appeared to be reliable
markers of disease severity (Figure 4B), regardless of the
genotype. 
Delayed clearance of RBC in patients with mild HS
allows a more gradual loss of the cell membrane (Figure
4G, Online Supplementary Figure S3), which results in bet-
ter conservation of RBC deformability (Figure 4B) and
the ability to form dense cells (Figure 4C-E, Online
Supplementary Figure S2). Direct measurements of mem-
brane shedding by monitoring plasma-borne vesicles is
challenging due to their fast sequestration and clear-
ance.32–34 However, higher levels of circulating RBC vesi-
cles were detected in plasma from patients with moder-
ate/severe HS (Figure 4G). This finding is in line with an
increase in other markers of membrane loss, such as
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Figure 4. Red blood cell density and stability as markers of severity in hereditary spherocytosis. Patients
with hereditary spherocytosis (HS) are grouped according to clinical severity (i.e. mild, moderate/severe and
splenectomized) (reference range in gray area). (A) Glycated hemoglobin (HbA1c) (mmol/mol), (B) maxi-
mum deformability (EImax), (C) hypertonic osmolarity at 50% of maximal elongation (Ohyper) (mOsmol/L), (D)
mean corpuscular hemoglobin concentration (MCHC) (g/L), (E) Position of M-fraction (%), (F) mean cell pro-
jected area (MPA) (in arbitrary units, a.u.), (G) red blood cell (RBC) vesicles (particles/1012 RBC/L plasma),
(H) eosin-5′-maleimide (EMA)-binding (%), (I) RBC distribution width (RDW) (percent coefficient of variation,
%CV), (J) mean cell projected area distribution width (MPA DW). Significant differences are represented by





changes in gross morphology toward a spherocytic form
(Online Supplementary Figure S3), as well as a higher num-
ber of microcytes, as determined by quantitative digital
microscopy (Online Supplementary Figure S4).
Red blood cell heterogeneity and deformability 
as a marker of clinical severity
Another parameter we found to reflect disease severity
in HS is RBC heterogeneity. Increases in RDW,
RDW/hemoglobin and MCHC/RDW ratios were suggest-
ed to be markers of the clinical severity of HS.35 We also
found in our study that RDW correlates with HS severity
(Figure 3B). However, since absolute RDW values are
known to vary between laboratories and depend on the
age and physical activity of the subjects,35 we also used
microscopy, confirming that patients with severe HS did
indeed have a broader range of RBC shapes and MPA DW
(Figure 4J, Online Supplementary Figure S3). 
Word of caution regarding automated detection of
hematocrit and mean corpuscular hemoglobin 
concentration in patients with hereditary spherocytosis 
MCHC was previously suggested to be prognostic for
the severity of HS in non-splenectomized patients.9,11 We
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Figure 5. Role of splenectomy on red blood cell parameters in hereditary spherocytosis. Blue circles represent healthy controls, black circles represent (unsplenec-
tomized) hereditary spherocytosis (HS) patients and red circles represent splenectomized HS patients. HS patients are grouped according to clinical severity (i.e.
mild, moderate/severe and splenectomized). (A) Red cell distribution width (RDW (percent coefficient of variation, %CV), (B) glycated hemoglobin (HbA1c)
(mmol/mol), (C) band 4.1a/4.1b ratio, (D) mean corpuscular hemoglobin concentration (MCHC) (g/L), (E) intracellular potassium (mmol/L), (F) eosin-5′-maleimide
(EMA)-binding hemoglobin (%), (G) maximum deformability (EImax), (H) hydration state of the red blood cells reflected by hypertonic osmolarity at 50% of maximal
elongation (Ohyper) (mOsmol/L), (I) 50% lysis point in the osmotic fragility test (g/L NaCl). Significant differences are noted: *P≤0.05, †P≤0.01 or ‡P≤0.001.
Table 2. Summary of parameters that characterize disease severity in hereditary spherocytosis. 
Disease Severity                               MCHC                      Density                    RDW            Reticulocytes            Deformability             Membrane loss 
                                                                                     (Percoll, Ohyper)                                                                          (Elmax)                    (vesiculation)
Mild                                                                ↑↑                                  ↑↑                                =                            ↑                                     ↓                                        ↑
Moderate/severe                                          ↑                                     ↑                                ↑↑                         ↑↑                                  ↓↓                                    ↑↑
Splenectomized                                           ↑↑                                    =                                  =                            ↑                                     =                                        =
The ↑ symbol indicates increased compared to healthy controls, ↓ indicates decreased compared to healthy controls and = indicates the same as in healthy controls. MCHC:





used a capillary-based method with determination of the
hematocrit to measure MCHC. In line with previous
observations,36–38 we found that automated measurements
of MCHC of pathological RBC are imprecise for HS
patients (see Online Supplementary Figure S5). Inaccuracy of
automated MCHC detection of dehydrated RBC has been
discussed for over 30 years.36 It results from a substantial
overestimation of MCV, both values being reliant on
hematocrit detection or calculation methods.39,40 As men-
tioned previously, others have shown that increased
hemoglobin concentrations correlate with milder disease
severity scores in HS.9,11 We show that MCHC, calculated
based on the capillary hematocrit, correlated with blood
hemoglobin content (Figures 1G, 3A, and 4D). 
Conclusions 
This study reveals the factors defining RBC longevity
and erythropoietic activity in patients with HS. These fac-
tors include membrane stability, which in turn depends on
the localization of mutations affecting vertical or horizon-
tal interactions within the membrane cytoskeleton and on
the presence of splenic filtering capacity. Mild HS is asso-
ciated with prolonged survival of RBC in the circulation,
allowing greater loss of membrane, which results in small-
er and denser RBC. Shorter-lived, unstable RBC from
patients with severe HS phenotype are more heteroge-
neous and less dense, as reflected by lower MCHC.
Parameters that specifically mark clinical severity in HS
are summarized in Table 2 and are RBC density (MCHC,
Percoll, Ohyper), RBC deformability (EImax), and RBC hetero-
geneity (RDW). These parameters may be used to monitor
the success of supportive therapy and assist in the develop-
ment of new personalized treatment regimens. 
Funding
Funding for the research leading to these results was received
from the European Seventh Framework Program under grant
agreement number 602121 (CoMMiTMenT) and from the
European Union’s Horizon 2020 Research and Innovation
Programme under grant agreement number 675115 — RELE-
VANCE — H2020-MSCA-ITN-2015/H2020-MSCA-ITN-
2015. This work was generated within the European Reference
Network on Rare Hematological Diseases (ERN-
EuroBloodNet) – FPA No. 739541
R. Huisjes et al.
346 haematologica | 2020; 105(2)
References 
1. Perrotta S, Gallagher PG, Mohandas N.
Hereditary spherocytosis. Lancet. 2008;372
(9647):1411-1426.
2. Morton NE, Mackinney  a a, Kosower N,
Schilling RF, Gray MP. Genetics of spherocy-
tosis. Am J Hum Genet. 1962;170-184.
3. Gallagher PG. Hereditary elliptocytosis:
spectrin and protein 4.1R. Semin Hematol.
2004;41(2):142-164.
4. Da Costa L, Mohandas N, Sorette M,
Grange MJ, Tchernia G, Cynober T.
Temporal differences in membrane loss lead
to distinct reticulocyte features in hereditary
spherocytosis and in immune hemolytic
anemia. Blood. 2001;98(10):2894-2899.
5. Lazarova E, Gulbis B, Oirschot B van, van
Wijk R. Next-generation osmotic gradient
ektacytometry for the diagnosis of heredi-
tary spherocytosis: interlaboratory method
validation and experience. Clin Chem Lab
Med. 2017;55(3):394-402.
6. Huisjes R, Bogdanova A, van Solinge WW,
Schiffelers RM, Kaestner L, van Wijk R.
Squeezing for life – properties of red blood
cell deformability. Front Physiol. 2018;9:656.
7. Michaels LA, Cohen AR, Zhao H, Raphael
RI, Manno CS. Screening for hereditary
spherocytosis by use of automated erythro-
cyte indexes. J Pediatr. 1997;130(6):957-960.
8. Cynober T, Mohandas N, Tchernia G. Red
cell abnormalities in hereditary spherocyto-
sis: Relevance to diagnosis and understanding
of the variable expression of clinical severity.
J Lab Clin Med. 1996;128(3):259-269.
9. Rocha S, Costa E, Rocha-Pereira P, et al.
Complementary markers for the clinical
severity classification of hereditary sphero-
cytosis in unsplenectomized patients. Blood
Cells Mol Dis. 2011;46(2):166-170.
10. Eber SW, Armbrust R, Schröter W. Variable
clinical severity of hereditary spherocytosis:
relation to erythrocytic spectrin concentra-
tion, osmotic fragility, and autohemolysis. J
Pediatr. 1990;117 (3):409-416.
11. Bolton-Maggs PHB, Langer JC, Iolascon A,
Tittensor P, King M-J, General Haematology
Task Force of the British Committee for
Standards in Haematology. Guidelines for
the diagnosis and management of hereditary
spherocytosis - 2011 update. Br J Haematol.
2012;156(1):37-49.
12. King MJ, Behrens J, Rogers C, Flynn C,
Greenwood D, Chambers K. Rapid flow
cytometric test for the diagnosis of mem-
brane cytoskeleton-associated haemolytic
anaemia. Br J Haematol. 2000;111 (3):924-
933.
13. Bosch FH, Werre JM, Schipper L, et al.
Determinants of red blood cell deformabili-
ty in relation to cell age. Eur J Haematol.
1994;52(1):35-41.
14. Waugh RE, Narla M, Jackson CW, Mueller
TJ, Suzuki T, Dale GL. Rheologic properties
of senescent erythrocytes: loss of surface
area and volume with red blood cell age.
Blood. 1992;79(5):1351-1358.
15. Bosman GJCGM. Survival of red blood cells
after transfusion: processes and conse-
quences. Front Physiol. 2013;4:376.
16. Vives Corrons JL, Besson I. Red cell mem-
brane Na+ transport systems in hereditary
spherocytosis: relevance to understanding
the increased Na+ permeability. Ann
Hematol. 2001;80(9):535-539.
17. Gallagher PG. Disorders of erythrocyte
hydration. Blood. 2017;130(25):2699-2708.
18. De Franceschi L, Olivieri O, Miraglia del
Giudice E, et al. Membrane cation and anion
transport activities in erythrocytes of hered-
itary spherocytosis: effects of different
membrane protein defects. Am J Hematol.
1997;55(3):121-128.
19. Makhro A, Huisjes R, Verhagen LP, et al. Red
cell properties after different modes of blood
transportation. Front Physiol. 2016;7:288.
20. Jokinen CH, Swaim WR, Nuttall FQ. A case
of hereditary xerocytosis diagnosed as a
result of suspected hypoglycemia and
observed low glycohemoglobin. J Lab Clin
Med. 2004;144(1):27-30.
21. Da Costa L, Suner L, Galimand J, et al.
Diagnostic tool for red blood cell membrane
disorders: assessment of a new generation
ektacytometer. Blood Cells Mol Dis.
2016;56(1):9-22.
22. Parpart AK, Lorenz PB, Parpart ER, Gregg JR,
Chase AM. The osmotic resistance (fragility)
of human red cells. J Clin Invest. 1947;26(4):
636-640.
23. King M-J, Telfer P, MacKinnon H, et al.
Using the eosin-5-maleimide binding test in
the differential diagnosis of hereditary sphe-
rocytosis and hereditary pyropoikilocytosis.
Cytometry B Clin Cytom. 2008;74(4):244-
250.
24. Ghosh S, Chakraborty I, Chakraborty M,
Mukhopadhyay A, Mishra R, Sarkar D.
Evaluating the morphology of erythrocyte
population: an approach based on atomic
force microscopy and flow cytometry.
Biochim Biophys Acta. 2016;1858(4):671-
681.
25. Lutz HU, Bogdanova A. Mechanisms tag-
ging senescent red blood cells for clearance
in healthy humans. Front Physiol. 2013;
4:387.
26. Makhro A, Kaestner L, Bogdanova A.
NMDA receptor activity in circulating red
blood cells: methods of detection. Methods
Mol Biol. 2017;1677:265-282.
27. Huisjes R, van Solinge WW, Levin MD, van
Wijk R, Riedl JA. Digital microscopy as a
screening tool for the diagnosis of hereditary
hemolytic anemia. Int J Lab Hematol.
2018;40(2):159-168.
28. van Vuren A, van der Zwaag B, Huisjes R et
al. The Complexity of Genotype-Phenotype
Correlations in Hereditary Spherocytosis: A
Cohort of 95 Patients. Hemasphere. 2019
Aug 7;3(4):e276.
29. Narla J, Mohandas N. Red cell membrane
disorders. Int J Lab Hematol. 2017;39 Suppl
1:47-52.
30. Chonat S, Risinger M, Dagaonkar N, et al.
The spectrum of alpha-spectrin associated
hereditary spherocytosis. Blood. 2015;126
(23):941.
31. Maciag M, Płochocka D, Adamowicz-
Salach A, Burzyńska B. Novel beta-spectrin
mutations in hereditary spherocytosis asso-
ciated with decreased levels of mRNA. Br J
Haematol. 2009;146(3):326-332.
32. Willekens FLA, Werre JM, Groenen-Döpp
YAM, Roerdinkholder-Stoelwinder B, de
Pauw B, Bosman GJCGM. Erythrocyte
vesiculation: a self-protective mechanism?
Br J Haematol. 2008;141 (4):549-556.
33. Ciana A, Achilli C, Gaur A, Minetti G.
Membrane remodelling and vesicle forma-
tion during ageing of human red blood Cells.
Cell Physiol Biochem. 2017;42(3):1127-
1138.
34. Willekens FLA, Werre JM, Kruijt JK, et al.
Liver Kupffer cells rapidly remove red blood
cell–derived vesicles from the circulation by
scavenger receptors. Blood. 2005;105(5):
2141-2145.
35. Salvagno GL, Sanchis-Gomar F, Picanza A,
Lippi G. Red blood cell distribution width: a
simple parameter with multiple clinical
applications. Crit Rev Clin Lab Sci. 2015;
52(2):86-105.
36. Mohandas N, Clark MR, Kissinger S, Bayer
C, Shohet SB. Inaccuracies associated with
the automated measurement of mean cell
hemoglobin concentration in dehydrated
cells. Blood. 1980;56(1):125-128.
37. Berda-Haddad Y, Faure C, Boubaya M, et al.
Increased mean corpuscular haemoglobin
concentration: artefact or pathological con-
dition? Int J Lab Hematol. 2017;39(1):32-41.
38. Zandecki M, Genevieve F, Gerard J, Godon
A. Spurious counts and spurious results on
haematology analysers: a review. Part II:
white blood cells, red blood cells, haemoglo-
bin, red cell indices and reticulocytes. Clin
Lab Haematol. 2007;29(1):21-41.
39. Kokholm G. Simultaneous measurements of
blood pH, pCO2, pO2 and concentrations of
hemoglobin and its derivates-a multicenter
study. Scand J Clin Lab Invest. 1990;50
(sup203):75-86.
40. O’Connor G, Molloy AM, Daly L, Scott JM.
Deriving a useful packed cell volume esti-
mate from haemoglobin analysis. J Clin
Pathol. 1994;47(1):78-79.
Phenotypic markers for hereditary spherocytosis
haematologica | 2020; 105(2) 347
